This leaflet answers some of the common questions about Invega Trinza. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist.

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.